Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]
Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]
Lilly unveils $3 billion production expansion in China [Yahoo! Finance]
Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.